{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:11:18Z","timestamp":1793146278296,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023MH109"],"award-info":[{"award-number":["ZR2023MH109"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81902656"],"award-info":[{"award-number":["81902656"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82072871"],"award-info":[{"award-number":["82072871"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012620","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["Nos. ts20070743"],"award-info":[{"award-number":["Nos. ts20070743"]}],"id":[{"id":"10.13039\/100012620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    PARP inhibitor (PARPi) resistance presents a significant challenge in ovarian cancer treatment, necessitating the development of effective therapeutic strategies to overcome this resistance and improve patient outcomes. Our study demonstrated that elevated expression of SRY-box 9 (SOX9) contributes to olaparib resistance in ovarian cancer. Mechanistically, the deubiquitinating enzyme USP28 was identified as a novel interacting partner of SOX9. USP28 inhibited the ubiquitination and subsequent degradation of SOX9, which is mediated by the E3 ubiquitin ligase FBXW7 during olaparib treatment. ChIP-Seq analysis revealed that SOX9 binds to the promoters of key DNA damage repair (DDR) genes (\n                    <jats:italic>SMARCA4<\/jats:italic>\n                    ,\n                    <jats:italic>UIMC1<\/jats:italic>\n                    , and\n                    <jats:italic>SLX4<\/jats:italic>\n                    ), thereby regulating DDR processes in ovarian cancer. Additionally, USP28 promoted olaparib resistance by stabilizing SOX9 protein and enhancing DNA damage repair. Furthermore, the USP28 specific inhibitor AZ1 reduced SOX9 protein stability and increased the sensitivity of ovarian cancer cells to olaparib. In conclusion, targeted inhibition of USP28 promoted ubiquitination-mediated degradation of SOX9, thereby impairing DNA damage repair capabilities and sensitizing ovarian cancer cells to PARPi. These findings elucidate the underlying mechanisms of PARPi resistance in ovarian cancer and suggest the potential efficacy of combining USP28 inhibitors with PARPi to overcome this resistance.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-07647-4","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:42:26Z","timestamp":1744764146000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["USP28 promotes PARP inhibitor resistance by enhancing SOX9-mediated DNA damage repair in ovarian cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Fang","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonghua","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongrong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunzhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5911-0242","authenticated-orcid":false,"given":"Beihua","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1399-2922","authenticated-orcid":false,"given":"Hanlin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"7647_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"7647_CR2","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40265-023-01934-0","volume":"83","author":"V Garg","year":"2023","unstructured":"Garg V, Oza AM. Treatment of ovarian cancer beyond PARP inhibition: current and future options. Drugs. 2023;83:1365\u201385.","journal-title":"Drugs"},{"key":"7647_CR3","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41571-024-00881-3","volume":"21","author":"PM Webb","year":"2024","unstructured":"Webb PM, Jordan SJ. Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024;21:389\u2013400.","journal-title":"Nat Rev Clin Oncol"},{"key":"7647_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1158\/0008-5472.CAN-23-4129","volume":"84","author":"V Ramanarayanan","year":"2024","unstructured":"Ramanarayanan V, Oberdoerffer P. AKTing on R loops makes for an ATRactive target in ovarian cancer therapy. Cancer Res. 2024;84:793\u20135.","journal-title":"Cancer Res"},{"key":"7647_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-48667-6","volume":"15","author":"B Ahn","year":"2024","unstructured":"Ahn B, Moon D, Kim HS, Lee C, Cho NH, Choi HK, et al. Histopathologic image-based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer. Nat Commun. 2024;15:4253.","journal-title":"Nat Commun"},{"key":"7647_CR6","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","volume":"366","author":"J Ledermann","year":"2012","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382\u201392.","journal-title":"N Engl J Med"},{"key":"7647_CR7","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1200\/JCO.22.01934","volume":"40","author":"WP Tew","year":"2022","unstructured":"Tew WP, Lacchetti C, Kohn EC. Panel PIitMoOCGE. Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022;40:3878\u201381.","journal-title":"J Clin Oncol"},{"key":"7647_CR8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","volume":"129","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer. 2023;129:904\u201316.","journal-title":"Br J Cancer"},{"key":"7647_CR9","doi-asserted-by":"crossref","unstructured":"Wang Y, Duval AJ, Adli M, Matei D. Biology-driven therapy advances in high-grade serous ovarian cancer. J Clin Investig. 2024;134:e174013.","DOI":"10.1172\/JCI174013"},{"key":"7647_CR10","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s00018-022-04543-4","volume":"79","author":"Z Ming","year":"2022","unstructured":"Ming Z, Vining B, Bagheri-Fam S, Harley V. SOX9 in organogenesis: shared and unique transcriptional functions. Cell Mol Life Sci. 2022;79:522.","journal-title":"Cell Mol Life Sci"},{"key":"7647_CR11","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","volume":"568","author":"FM Behan","year":"2019","unstructured":"Behan FM, Iorio F, Picco G, Goncalves E, Beaver CM, Migliardi G, et al. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature. 2019;568:511\u20136.","journal-title":"Nature"},{"key":"7647_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188517","volume":"1875","author":"M Panda","year":"2021","unstructured":"Panda M, Tripathi SK, Biswal BK. SOX9: An emerging driving factor from cancer progression to drug resistance. Biochim Biophys Acta Rev Cancer. 2021;1875:188517.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"7647_CR13","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1016\/j.drudis.2022.05.022","volume":"27","author":"SK Tripathi","year":"2022","unstructured":"Tripathi SK, Sahoo RK, Biswal BK. SOX9 as an emerging target for anticancer drugs and a prognostic biomarker for cancer drug resistance. Drug Discov Today. 2022;27:2541\u201350.","journal-title":"Drug Discov Today"},{"key":"7647_CR14","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.1038\/s41388-018-0656-7","volume":"38","author":"G Domenici","year":"2019","unstructured":"Domenici G, Aurrekoetxea-Rodriguez I, Simoes BM, Rabano M, Lee SY, Millan JS, et al. A Sox2-Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells. Oncogene. 2019;38:3151\u201369.","journal-title":"Oncogene"},{"key":"7647_CR15","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1038\/s41388-020-01402-z","volume":"39","author":"H Yang","year":"2020","unstructured":"Yang H, Geng YH, Wang P, Yang H, Zhou YT, Zhang HQ, et al. Extracellular ATP promotes breast cancer invasion and chemoresistance via SOX9 signaling. Oncogene. 2020;39:5795\u2013810.","journal-title":"Oncogene"},{"key":"7647_CR16","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.ygyno.2019.03.099","volume":"153","author":"M Sherman-Samis","year":"2019","unstructured":"Sherman-Samis M, Onallah H, Holth A, Reich R, Davidson B. SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma. Gynecol Oncol. 2019;153:651\u201360.","journal-title":"Gynecol Oncol"},{"key":"7647_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154602","volume":"248","author":"R Lu","year":"2023","unstructured":"Lu R, Tang P, Zhang D, Lin S, Li H, Feng X, et al. SOX9\/NFIA promotes human ovarian cancer metastasis through the Wnt\/beta-catenin signaling pathway. Pathol Res Pract. 2023;248:154602.","journal-title":"Pathol Res Pract"},{"key":"7647_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.gene.2014.03.037","volume":"542","author":"G Raspaglio","year":"2014","unstructured":"Raspaglio G, Petrillo M, Martinelli E, Li Puma DD, Mariani M, De Donato M, et al. Sox9 and Hif-2alpha regulate TUBB3 gene expression and affect ovarian cancer aggressiveness. Gene. 2014;542:173\u201381.","journal-title":"Gene"},{"key":"7647_CR19","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1002\/jcb.26865","volume":"120","author":"S Xiao","year":"2019","unstructured":"Xiao S, Li Y, Pan Q, Ye M, He S, Tian Q, et al. MiR-34c\/SOX9 axis regulates the chemoresistance of ovarian cancer cell to cisplatin-based chemotherapy. J Cell Biochem. 2019;120:2940\u201353.","journal-title":"J Cell Biochem"},{"key":"7647_CR20","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/s12276-022-00809-w","volume":"54","author":"H Ma","year":"2022","unstructured":"Ma H, Qi G, Han F, Peng J, Yuan C, Kong B. PBK drives PARP inhibitor resistance through the TRIM37\/NFkappaB axis in ovarian cancer. Exp Mol Med. 2022;54:999\u20131010.","journal-title":"Exp Mol Med"},{"key":"7647_CR21","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ygyno.2017.09.029","volume":"147","author":"C Qiu","year":"2017","unstructured":"Qiu C, Lu N, Wang X, Zhang Q, Yuan C, Yan S, et al. Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium. Gynecol Oncol. 2017;147:634\u201341.","journal-title":"Gynecol Oncol"},{"key":"7647_CR22","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.15252\/embj.201693889","volume":"35","author":"A Suryo Rahmanto","year":"2016","unstructured":"Suryo Rahmanto A, Savov V, Brunner A, Bolin S, Weishaupt H, Malyukova A, et al. FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. EMBO J. 2016;35:2192\u2013212.","journal-title":"EMBO J"},{"key":"7647_CR23","doi-asserted-by":"publisher","first-page":"8855","DOI":"10.1093\/nar\/gkw748","volume":"44","author":"X Hong","year":"2016","unstructured":"Hong X, Liu W, Song R, Shah JJ, Feng X, Tsang CK, et al. SOX9 is targeted for proteasomal degradation by the E3 ligase FBW7 in response to DNA damage. Nucleic Acids Res. 2016;44:8855\u201369.","journal-title":"Nucleic Acids Res"},{"key":"7647_CR24","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1182\/blood-2011-08-375014","volume":"119","author":"D Flugel","year":"2012","unstructured":"Flugel D, Gorlach A, Kietzmann T. GSK-3beta regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1alpha. Blood. 2012;119:1292\u2013301.","journal-title":"Blood"},{"key":"7647_CR25","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1158\/0008-5472.CAN-14-1726","volume":"75","author":"ME Diefenbacher","year":"2015","unstructured":"Diefenbacher ME, Chakraborty A, Blake SM, Mitter R, Popov N, Eilers M, et al. Usp28 counteracts Fbw7 in intestinal homeostasis and cancer. Cancer Res. 2015;75:1181\u20136.","journal-title":"Cancer Res"},{"key":"7647_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.celrep.2018.03.076","volume":"23","author":"TA Knijnenburg","year":"2018","unstructured":"KnijnenburgTA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, et al. Genomic and molecular landscape of DNA damage repair deficiency across The Cancer Genome Atlas. Cell Rep. 2018;23:239\u201354.e236.","journal-title":"Cell Rep"},{"key":"7647_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35715-2","volume":"13","author":"T Fan","year":"2022","unstructured":"Fan T, Kang H, Wu D, Zhu X, Huang L, Wu J, et al. Arabidopsis gamma-H2A.X-INTERACTING PROTEIN participates in DNA damage response and safeguards chromatin stability. Nat Commun. 2022;13:7942.","journal-title":"Nat Commun"},{"key":"7647_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25643-y","volume":"12","author":"IE Wassing","year":"2021","unstructured":"Wassing IE, Graham E, Saayman X, Rampazzo L, Ralf C, Bassett A, et al. The RAD51 recombinase protects mitotic chromatin in human cells. Nat Commun. 2021;12:5380.","journal-title":"Nat Commun"},{"key":"7647_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202001018","volume":"7","author":"N Shao","year":"2020","unstructured":"Shao N, Huang H, Idris M, Peng X, Xu F, Dong S, et al. KEAP1 Mutations Drive Tumorigenesis by suppressing SOX9 ubiquitination and degradation. Adv Sci. 2020;7:2001018.","journal-title":"Adv Sci"},{"key":"7647_CR30","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1002\/glia.23992","volume":"69","author":"W Liu","year":"2021","unstructured":"Liu W, Ge X, Zhou Z, Jiang D, Rong Y, Wang J, et al. Deubiquitinase USP18 regulates reactive astrogliosis by stabilizing SOX9. Glia. 2021;69:1782\u201398.","journal-title":"Glia"},{"key":"7647_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade5584","volume":"9","author":"Y Wu","year":"2023","unstructured":"Wu Y, Shen S, Chen J, Ni W, Wang Q, Zhou H, et al. Metabolite asymmetric dimethylarginine (ADMA) functions as a destabilization enhancer of SOX9 mediated by DDAH1 in osteoarthritis. Sci Adv. 2023;9:eade5584.","journal-title":"Sci Adv"},{"key":"7647_CR32","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1111\/cas.15509","volume":"113","author":"X Sun","year":"2022","unstructured":"Sun X, Cai M, Wu L, Zhen X, Chen Y, Peng J, et al. Ubiquitin-specific protease 28 deubiquitinates TCF7L2 to govern the action of the Wnt signaling pathway in hepatic carcinoma. Cancer Sci. 2022;113:3463\u201375.","journal-title":"Cancer Sci"},{"key":"7647_CR33","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/ncb1601","volume":"9","author":"N Popov","year":"2007","unstructured":"Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol. 2007;9:765\u201374.","journal-title":"Nat Cell Biol"},{"key":"7647_CR34","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1093\/nar\/gkae004","volume":"52","author":"C Jin","year":"2024","unstructured":"Jin C, Einig E, Xu W, Kollampally RB, Schlosser A, Flentje M, et al. The dimeric deubiquitinase USP28 integrates 53BP1 and MYC functions to limit DNA damage. Nucleic Acids Res. 2024;52:3011\u201330.","journal-title":"Nucleic Acids Res"},{"issue":"Suppl","key":"7647_CR35","first-page":"17","volume":"53","author":"K Shinmi","year":"1986","unstructured":"Shinmi K. [Nerve fiber connections in the hypothalamus]. Kokubyo Gakkai Zasshi. 1986;53(Suppl):17\u201325.","journal-title":"Kokubyo Gakkai Zasshi"},{"key":"7647_CR36","doi-asserted-by":"publisher","first-page":"3407","DOI":"10.1172\/JCI73733","volume":"124","author":"ME Diefenbacher","year":"2014","unstructured":"Diefenbacher ME, Popov N, Blake SM, Schulein-Volk C, Nye E, Spencer-Dene B, et al. The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer. J Clin Investig. 2014;124:3407\u201318.","journal-title":"J Clin Investig"},{"key":"7647_CR37","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41418-023-01173-6","volume":"30","author":"CR Maier","year":"2023","unstructured":"Maier CR, Hartmann O, Prieto-Garcia C, Al-Shami KM, Schlicker L, Vogel FCE, et al. USP28 controls SREBP2 and the mevalonate pathway to drive tumour growth in squamous cancer. Cell Death Differ. 2023;30:1710\u201325.","journal-title":"Cell Death Differ"},{"key":"7647_CR38","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41418-021-00875-z","volume":"29","author":"C Prieto-Garcia","year":"2022","unstructured":"Prieto-Garcia C, Hartmann O, Reissland M, Fischer T, Maier CR, Rosenfeldt M, et al. Inhibition of USP28 overcomes Cisplatin-resistance of squamous tumors by suppression of the Fanconi anemia pathway. Cell Death Differ. 2022;29:568\u201384.","journal-title":"Cell Death Differ"},{"key":"7647_CR39","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911101","volume":"12","author":"C Prieto-Garcia","year":"2020","unstructured":"Prieto-Garcia C, Hartmann O, Reissland M, Braun F, Fischer T, Walz S, et al. Maintaining protein stability of \u2206Np63 via USP28 is required by squamous cancer cells. EMBO Mol Med. 2020;12:e11101.","journal-title":"EMBO Mol Med"},{"key":"7647_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40164-023-00389-z","volume":"12","author":"X Ren","year":"2023","unstructured":"Ren X, Jiang M, Ding P, Zhang X, Zhou X, Shen J, et al. Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development. Exp Hematol Oncol. 2023;12:27.","journal-title":"Exp Hematol Oncol"},{"key":"7647_CR41","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13046-023-02767-1","volume":"42","author":"S Chen","year":"2023","unstructured":"Chen S, Leng P, Guo J, Zhou H. FBXW7 in breast cancer: mechanism of action and therapeutic potential. J Exp Clin Cancer Res. 2023;42:226.","journal-title":"J Exp Clin Cancer Res"},{"key":"7647_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01548-2","volume":"21","author":"J Fan","year":"2022","unstructured":"Fan J, Bellon M, Ju M, Zhao L, Wei M, Fu L, et al. Clinical significance of FBXW7 loss of function in human cancers. Mol Cancer. 2022;21:87.","journal-title":"Mol Cancer"},{"key":"7647_CR43","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.semcancer.2015.09.006","volume":"36","author":"CA Cremona","year":"2016","unstructured":"Cremona CA, Sancho R, Diefenbacher ME, Behrens A. Fbw7 and its counteracting forces in stem cells and cancer: oncoproteins in the balance. Semin Cancer Biol. 2016;36:52\u201361.","journal-title":"Semin Cancer Biol"},{"key":"7647_CR44","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/s41374-022-00812-9","volume":"102","author":"H Zhu","year":"2022","unstructured":"Zhu H, Wang X, Zhou X, Lu S, Gu G, Liu C. E3 ubiquitin ligase FBXW7 enhances radiosensitivity of non-small cell lung cancer cells by inhibiting SOX9 regulation of CDKN1A through ubiquitination. Lab Investig. 2022;102:1203\u201313.","journal-title":"Lab Investig"},{"key":"7647_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13045-020-0845-z","volume":"13","author":"XL Ma","year":"2020","unstructured":"Ma XL, Hu B, Tang WG, Xie SH, Ren N, Guo L, et al. CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma. J Hematol Oncol. 2020;13:11.","journal-title":"J Hematol Oncol"},{"key":"7647_CR46","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1111\/cas.14193","volume":"110","author":"Y Qian","year":"2019","unstructured":"Qian Y, Wu X, Yokoyama Y, Okuzaki D, Taguchi M, Hirose H, et al. E-cadherin-Fc chimera protein matrix enhances cancer stem-like properties and induces mesenchymal features in colon cancer cells. Cancer Sci. 2019;110:3520\u201332.","journal-title":"Cancer Sci"},{"key":"7647_CR47","doi-asserted-by":"crossref","unstructured":"Voronkova MA, Rojanasakul LW, Kiratipaiboon C, Rojanasakul Y. The SOX9-aldehyde dehydrogenase axis determines resistance to chemotherapy in non-small-cell lung cancer. Mol Cell Biol. 2020;40:e00307-19.","DOI":"10.1128\/MCB.00307-19"},{"key":"7647_CR48","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1158\/0008-5472.CAN-15-2834","volume":"76","author":"MJ Schultz","year":"2016","unstructured":"Schultz MJ, Holdbrooks AT, Chakraborty A, Grizzle WE, Landen CN, Buchsbaum DJ, et al. The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype. Cancer Res. 2016;76:3978\u201388.","journal-title":"Cancer Res"},{"key":"7647_CR49","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/s41416-018-0338-9","volume":"119","author":"X Yuan","year":"2018","unstructured":"Yuan X, Li J, Coulouarn C, Lin T, Sulpice L, Bergeat D, et al. SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance. Br J Cancer. 2018;119:1358\u201366.","journal-title":"Br J Cancer"},{"key":"7647_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.646542","volume":"8","author":"Y Liu","year":"2021","unstructured":"Liu Y, Wu H, Luo T, Luo Q, Meng Z, Shi Y, et al. The SOX9-MMS22L axis promotes oxaliplatin resistance in colorectal cancer. Front Mol Biosci. 2021;8:646542.","journal-title":"Front Mol Biosci"},{"key":"7647_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer. 2020;19:107.","journal-title":"Mol Cancer"},{"key":"7647_CR52","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1038\/s41388-023-02773-9","volume":"42","author":"SM Navickas","year":"2023","unstructured":"Navickas SM, Giles KA, Brettingham-Moore KH, Taberlay PC. The role of chromatin remodeler SMARCA4\/BRG1 in brain cancers: a potential therapeutic target. Oncogene. 2023;42:2363\u201373.","journal-title":"Oncogene"},{"key":"7647_CR53","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1126\/science.1139621","volume":"316","author":"H Kim","year":"2007","unstructured":"Kim H, Chen J, Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science. 2007;316:1202\u20135.","journal-title":"Science"},{"key":"7647_CR54","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/10409238.2021.1881433","volume":"56","author":"SJ Young","year":"2021","unstructured":"Young SJ, West SC. Coordinated roles of SLX4 and MutSbeta in DNA repair and the maintenance of genome stability. Crit Rev Biochem Mol Biol. 2021;56:157\u201377.","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"7647_CR55","doi-asserted-by":"crossref","unstructured":"Jordheim LP. PARP inhibitors and proteins interacting with SLX4. Cancers. 2023, 15.","DOI":"10.3390\/cancers15030997"},{"key":"7647_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.768264","volume":"11","author":"H Chen","year":"2021","unstructured":"Chen H, He Y, Wen X, Shao S, Liu Y, Wang J. SOX9: advances in gynecological malignancies. Front Oncol. 2021;11:768264.","journal-title":"Front Oncol"},{"key":"7647_CR57","doi-asserted-by":"crossref","unstructured":"Patzke JV, Sauer F, Nair RK, Endres E, Proschak E, Hernandez-Olmos V, et al. Structural basis for the bi-specificity of USP25 and USP28 inhibitors. EMBO Rep. 2024;25:2950\u201373.","DOI":"10.1038\/s44319-024-00167-w"},{"key":"7647_CR58","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41568-023-00633-y","volume":"23","author":"G Dewson","year":"2023","unstructured":"Dewson G, Eichhorn PJA, Komander D. Deubiquitinases in cancer. Nat Rev Cancer. 2023;23:842\u201362.","journal-title":"Nat Rev Cancer"},{"key":"7647_CR59","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.molcel.2021.10.027","volume":"82","author":"SM Lange","year":"2022","unstructured":"Lange SM, Armstrong LA, Kulathu Y. Deubiquitinases: from mechanisms to their inhibition by small molecules. Mol Cell. 2022;82:15\u201329.","journal-title":"Mol Cell"},{"key":"7647_CR60","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1021\/acschembio.7b00334","volume":"12","author":"JD Wrigley","year":"2017","unstructured":"Wrigley JD, Gavory G, Simpson I, Preston M, Plant H, Bradley J, et al. Identification and characterization of dual inhibitors of the USP25\/28 deubiquitinating enzyme subfamily. ACS Chem Biol. 2017;12:3113\u201325.","journal-title":"ACS Chem Biol"},{"key":"7647_CR61","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.bbrc.2022.11.055","volume":"638","author":"J Shen","year":"2023","unstructured":"Shen J, Xie M, Xu Y, Qian Q, Qiu T, Shi W, et al. Identification of the deubiquitinase USP28 as a novel molecular therapeutic target of ovarian cancer. Biochem Biophys Res Commun. 2023;638:184\u201391.","journal-title":"Biochem Biophys Res Commun"},{"key":"7647_CR62","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrd3753","volume":"11","author":"A Dlugosz","year":"2012","unstructured":"Dlugosz A, Agrawal S, Kirkpatrick P. Vismodegib. Nat Rev Drug Discov. 2012;11:437\u20138.","journal-title":"Nat Rev Drug Discov"},{"key":"7647_CR63","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/febs.15461","volume":"288","author":"H Wang","year":"2021","unstructured":"Wang H, Meng Q, Ding Y, Xiong M, Zhu M, Yang Y, et al. USP28 and USP25 are downregulated by Vismodegib in vitro and in colorectal cancer cell lines. FEBS J. 2021;288:1325\u201342.","journal-title":"FEBS J"},{"key":"7647_CR64","doi-asserted-by":"crossref","unstructured":"Ruiz EJ, Pinto-Fernandez A, Turnbull AP, Lan L, Charlton TM, Scott HC, et al. USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma. Elife. 2021, 10:e71596.","DOI":"10.7554\/eLife.71596"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07647-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07647-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07647-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T02:02:51Z","timestamp":1744768971000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07647-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7647"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07647-4","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"3 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"HGSOC tissues were collected from primary ovarian cancer patients with no prior history of surgery or chemotherapy at Qilu Hospital of Shandong University. The present study was approved by the Ethics Committee of Qilu Hospital of Shandong University and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"305"}}